Rpl13a Antibodies

60S ribosomal protein L13a (Rpl13a)

Connected with ribosomes but isn't required for canonical ribosome function and contains extra-ribosomal functions (By similarity). Part of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma- triggered transcript-selective translation inhibition in inflammation processes.

Upon interferon-gamma activation and subsequent phosphorylation dissociates from the ribosome and assembles to the GAIT complex which binds to stem loop- containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation. From the GAIT complex interacts with m7G cap-bound eIF4G at or close to the eIF3-binding website and blocks the recruitment of the 43S ribosomal complex.

Gene Information

Mouse
Gene Name:	Rpl13a
Uniprot:	P19253
Entrez:	22121

Family

Belongs to:
universal ribosomal protein uL13 family

Alternative Names

60S ribosomal protein L13a; ribosomal protein L13a; tissue specific transplantation antigen 1,23 kDa highly basic protein; TSTA1

Molecular Weight

Mass (kDA):
23.464 kDA

Genomic Context

Mouse
Location:	7 B3|7 29.14 cM
Sequence:	7;

Diseases

• Malignant Neoplasms
• Neoplasms
• Carcinoma
• Brain Ischemia
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Ischemia
• Cerebral Ischemia
• Neoplasm Metastasis
• Hypoxia
• Complications Of Diabetes Mellitus
• Malignant Paraganglionic Neoplasm
• Diabetes Mellitus

• Prostatic Neoplasms
• Inflammation
• Infarction
• Degenerative Polyarthritis
• Osteosarcoma
• Myocardial Infarction
• Malignant Neoplasm Of Prostate

Pathways

• Reverse Transcription
• Translation
• Methylation
• Pathogenesis
• Proteolysis
• Cell Proliferation
• Dna Methylation
• Larval Development
• Localization
• Stem Cell Differentiation
• Immune Response
• Regulation Of Gene Expression
• Embryo Development

• Cell Cycle
• Blastocyst Development
• Cell Differentiation
• Histone Acetylation
• Blood Circulation
• Translational Elongation
• Drug Resistance

PTMs

• Nitrosylation
• Reduction

• Acetylation
• Methylation

• Oxidation

Research Areas

• Stem Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/Rpl13a

Synthesis and Best Uses of the RPL13A Marker

Synthesis and Best Uses for The RPL13A Genome - How To Make Them

Syn

Molecular markers are useful in the diagnosis of bone tumors, and research is ongoing to understand the mechanisms involved in bone tumorigenesis. The RPL13A product gene contains a C-terminal extension of the globular, eukaryotic globular protein and several putative signals for nuclear localization. These proteins also contain RNA-binding sequences. This marker is able to detect bone tumors and has many other potential uses.

The RPL27A tumor suppressor gene is important, but it is poorly understood. The expression of the RPL27A gene in cancer cells is a potential therapeutic target. It has been implicated in the formation and metastasis TNBC. This suggests that Rpl27A might play a role for tumor metastasis. Rpl13a also is expressed in various types of cancer cells including breast and colon.

The RPL13A genome has low variability among donors, passing numbers, and differentiation circumstances. In addition, it ranks highly for chondrogenesis and osteogenesis. It is not a good marker for adipogenesis. It is a good candidate for a ribosomal signaling protein marker. Its arg68 amino acids are critical for binding rRNA, and incorporation into the ribosomes.

Synthesis

This marker was identified first by synthesizing the RPL13A gene's protein sequence using a Recombinant Plasmid. The RPL13A gene has been found to be extremely conserved in mammals and is essential for the development new vaccines. Evolution strongly influences the sequences of these proteins, which is why there is so much variation in virus-host interactions.

Synthesis and use of primers

Primers are short oligonucleotides ranging in length from 20 to 40 nucleotides. These serve as starting points for DNA-synthesis during PCR. They are useful in obtaining specific DNA fragments to be used in cloning and quantitative Real Time PCR. In this study, we used the RPL13A marker to design primer pairs using this gene. This research has important implications in the development of new technologies to enhance DNA amplification.

The primers were developed to amplify KLK4T2 and KLK4T2 transcripts. They hybridized to sequences within KLK4 exons 3 & 4, respectively. The 262 bp difference in the two primers resulted in slightly larger products. The resulting products were respectively 1.3 and 0.99 kb. The primer pair was intended to amplify the rpl13A genes.

The box plot below shows the RPL13A gene expression ratio for each parent. The box plots show median values, 1st quartile and 3rd quarteriles. Whiskers indicate the 2.5 to 97.5 percentiles. The RPL13A gene expression in heterozygous mouse was lower than that of homozygous.

qPCR assay

The RPL13AqPCR assay is used for the detection and quantification of genes in samples. It is used in gene doping studies. The assay works well when used with dried blood spot (DBS). The qPCR method measures the DNA concentration in a sample using a standard POCT technique. The PCR results are normalized with the concentration of a control gene such as 18s rRNA.

Normalization

Multiple genes have been examined for their ability predict the occurrences of cancer in women. Many of these genes can only be expressed at low levels in the female ovarian tissues. To test the potential of RPL13A for determining the incidence of breast cancer, we performed a GeNorm analysis to select candidate gene expression levels. GeNorm analysis involves three steps to select candidate genes: stepwise exclusion of genes with low expression stability (M) and pairwise variation of normalization factors for n+1 genes.

Quantitative real-time PCR normalizes the expression of many genes by comparing them with a reference gene. In ideal cases, the reference gene is expressed at the exact same level in all samples at all developmental stages and before and after manipulation. However, many traditional references genes show varying expression under different conditions. They are not ideal candidates for normalization. Alternative reference genes may be used.

Researchers recently compared two genes for a GAPDH-related gene. While comparing these genes, they found that CD31 had a higher relative fold-change than the other two. GAPDH could also normalize expression levels of many genes, such as the RPL13A gene. Further, the study also found that GAPDH, a marker for the fibroblast growth factor receptor, was also associated with higher levels of human cancer cells than CD31 or GAPDH.

Reference gene

Many cell cultures require the RPL13A gene. This marker is very specific for rhodopsin which plays an important part in the regulation and maintenance of the cytoskeleton. It is also an important part of many cancer-related tests, including amplification of RNA from cancer cells. RPL13A has a wide range of uses, but many people are not familiar with how to apply it in their research.

Many biological assays can detect antibodies for the RPL13A protein. These antibodies react with RPL13A using animal samples and can be monoclonal (or polyclonal) Boster Bio uses rabbit and mouse to create antibodies against this marker. The RPL13A genes is involved in the differentiation bone mesenchymal-derived stem cells into neurons. This is known as neurite outgrowth inhibition.

RPL13A has a high level of specificity compared to other markers. RPL13A is extremely specific but complex, making it an invaluable tool for studying evolution of many species. Boster Bio has also released RPL13A–LysG which is derived form a reference gene.